|1.||Kido, Hiroshi: 5 articles (01/2012 - 10/2006)|
|2.||Chida, Junji: 5 articles (01/2012 - 10/2006)|
|3.||López, Miguel: 4 articles (03/2015 - 03/2007)|
|4.||Yamaguchi, Miyoko: 4 articles (01/2012 - 05/2008)|
|5.||Yao, Dengbing: 4 articles (01/2012 - 10/2006)|
|6.||Vladutiu, Georgirene D: 4 articles (10/2009 - 11/2002)|
|7.||Angelini, Corrado: 3 articles (04/2015 - 01/2011)|
|8.||Yamaguchi, Seiji: 3 articles (05/2014 - 10/2002)|
|9.||Hegardt, Fausto G: 3 articles (01/2014 - 03/2007)|
|10.||Asins, Guillermina: 3 articles (01/2014 - 03/2007)|
11/01/2012 - "In this article, we describe recent preclinical studies suggesting that a gene usually expressed only in the brain, carnitine palmitoyltransferase (CPT)1C, promotes cancer cell survival and tumor growth. "
05/15/2011 - "Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress."
12/01/2010 - "Endurance training restored maximal CPT I and CPT II activity in the tumor-bearing animals (p<0.0001). "
10/01/1993 - "Carnitine palmitoyltransferase activity was not altered, even in the presence of a large tumor burden. "
10/01/1993 - "Tumor-induced alterations in hepatic malic enzyme and carnitine palmitoyltransferase activity."
12/01/2015 - "Timely diagnosis of CPT II deficiency in this case prevented further potentially devastating episodes of rhabdomyolysis by avoiding triggering factors. "
10/21/2013 - "In the 3 distinct clinical subtypes of CPT II deficiency, adult onset myopathic form shows mild clinical manifestations, characterized by recurrent rhabdomyolysis after intense physical stress. "
03/01/2013 - "[Anesthetic management of a patient with carnitine palmitoyltransferase deficiency with a history of rhabdomyolysis]."
10/01/2010 - "Late-onset CPT II is characterised only by episodic rhabdomyolysis on severe exercise. "
07/01/2010 - "Carnitine palmitoyltransferase 2 (CPT2) deficiency is a rare mitochondrial fatty acid oxidation (FAO) disorder characterized by myalgia, exercise intolerance, and rhabdomyolysis. "
09/01/2005 - "These changes in metabolic zonation, together with decreased CPT II activity, may contribute to the aggravation of cachexia."
09/01/2005 - "The distribution of CPT II and L-FABP (by immunohistochemistry) within the acinus was modified by cachexia: whereas CPT II positivity was restricted to the PV zone, L-FABP labelling shifted from periportal (control) to perivenous (TB) zone. "
07/15/2011 - "Impaired fatty acid oxidation mainly resulting from the decrease of carnitine palmitoyltransferase I and II activities in the liver is an important factor that contributes to cancer cachexia . "
01/01/2015 - "<smlcap>L</smlcap>-Carnitine Ameliorates Cancer Cachexia in Mice Partly via the Carnitine Palmitoyltransferase-Associated PPAR-x03B3; Signaling Pathway."
|4.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
|5.||Mental Retardation (Idiocy)
|2.||Fatty Acids (Saturated Fatty Acids)
|4.||Peroxisome Proliferator-Activated Receptors (PPAR)
|6.||Messenger RNA (mRNA)
|7.||Carnitine O-Palmitoyltransferase (Carnitine Palmitoyltransferase II)
|8.||Malonyl Coenzyme A (Malonyl CoA)
|9.||Acyl Coenzyme A (Acyl CoA)
|1.||Drug Administration Schedule
|2.||Drug Therapy (Chemotherapy)
|3.||Cardiopulmonary Resuscitation (CPR)
|4.||Transplantation (Transplant Recipients)